<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888377</url>
  </required_header>
  <id_info>
    <org_study_id>GN ASPIRIN Follow Up</org_study_id>
    <nct_id>NCT04888377</nct_id>
  </id_info>
  <brief_title>ASPIRIN: Neurodevelopmental Follow-up Trial</brief_title>
  <official_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction in Nulliparas (ASPIRIN): Neurodevelopmental Follow-up Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Global Network for Women's and Children's Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Global Network for Women's and Children's Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 620 children will be enrolled in this study from six sites in sub-Saharan Africa,&#xD;
      South Asia, and Latin America. Half of the children's mothers will have taken aspirin and&#xD;
      half will have taken placebo. This will allow the researchers to compare results of the two&#xD;
      groups of children and determine if children exposed antenatally to low dose aspirin will&#xD;
      have scores on the Bayley Scales of Infant Development-III (BSID-III) examination at 36&#xD;
      months of life (+/-3months) that are not inferior to the child's peers who were not exposed&#xD;
      (i.e., by no more than a margin of 4 points).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 250 million children under the age of 511 worldwide are at risk for not&#xD;
      achieving their developmental potential; 52.9 million children under five years of age in&#xD;
      low- and middle-income country (LMIC) settings have neurodevelopmental delays. Compounding&#xD;
      the issue is preterm birth (more common in LMICs) which has consistently been identified as a&#xD;
      cause of neurodevelopmental delay. A recent review reported that out of the estimated 13&#xD;
      million preterm infants who survive beyond the first month, 0.9 million will suffer long term&#xD;
      neurodevelopmental impairment, with 345,000 moderately or severely affected. This burden&#xD;
      places a significant strain on the families, healthcare systems and societies that provide&#xD;
      care for these children. Data from other Global Network participating sites (Guatemala,&#xD;
      Democratic Republic of Congo, Zambia and Pakistan) also found strikingly high rates of&#xD;
      stunting ranging from 44% to 66%, among infants and toddlers. Poverty additionally&#xD;
      contributes to the attainment of optimal neurodevelopment. As such, any study of&#xD;
      neurodevelopment should at least document these potential confounders.&#xD;
&#xD;
      Aspirin has been shown to predominantly affect both the COX-1 pathway which is involved in&#xD;
      thrombosis and the COX-2 pathway, which affects inflammation through the production of&#xD;
      Aspirin Triggered Lipoxins. More specifically, aspirin has been shown to inhibit the&#xD;
      production of IL-6, IL-1B, CRP and TNF-Î± all of which have been shown to negatively affect&#xD;
      child neurodevelopment and be involved in preeclampsia and preterm birth.&#xD;
&#xD;
      This will be a prospective masked matched cohort study of children between 33 and 39 months&#xD;
      (mean 36 months) of age whose mothers were randomized in the ASPIRIN trial (1:1&#xD;
      Aspirin-Placebo), who will be evaluated using the BSID-III. Additionally, the Family&#xD;
      Resources and Context questionnaire will be performed to adjust for the local context and the&#xD;
      ASQ-3 will be administered as a secondary screen. Recognizing the significant role that&#xD;
      preterm birth plays in neurodevelopment, the investigators will include 100 (50 in each&#xD;
      group) children who were delivered before 37 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BSID-III Examination</measure>
    <time_frame>36 months</time_frame>
    <description>BSID-III examination at 36 months of life (+/-3months) with margins of 0-4 points. Minimum score of 1 and maximum score of 130. The lower score is a bad outcome and a higher score is good outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASQ-3</measure>
    <time_frame>36 months</time_frame>
    <description>Accepted and Validated screening tool for neurodevelopment at 36 months of life (+/-3months). Minimum score of 0 and maximum score of 60. The lower score is a bad outcome and a higher score is good outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Infant Feeding Index</measure>
    <time_frame>36 months</time_frame>
    <description>Collection of information on breastfeeding history, feeding practices, food frequency, and recent dietary history. This is a questionnaire to determine the child's availability to basic food sources.</description>
  </other_outcome>
  <other_outcome>
    <measure>Family Care Indicators</measure>
    <time_frame>36 months</time_frame>
    <description>Questionnaire to indicate the basic resources available to the participant (i.e. housing, medical care, etc).</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Neurodevelopmental Abnormality</condition>
  <arm_group>
    <arm_group_label>Antenatal exposure to low dose aspirin</arm_group_label>
    <description>Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antenatal exposure to Placebo</arm_group_label>
    <description>Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.</description>
    <arm_group_label>Antenatal exposure to low dose aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participant's mothers were administered placebo throughout their pregnancy with the participant.</description>
    <arm_group_label>Antenatal exposure to Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of approximately 620 children, between 33 and 39 months&#xD;
        of age, whose mothers were included in the ASPIRIN trial.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mother was enrolled in the GN ASPIRIN trial&#xD;
&#xD;
          -  Mother consented to be recontacted&#xD;
&#xD;
          -  Child's parents or guardians are willing and able to give consent&#xD;
&#xD;
          -  Child is between 33-39 months of age&#xD;
&#xD;
          -  Child does not have significant congenital anomaly (blind or deaf) that would affect&#xD;
             them from completing study assessments&#xD;
&#xD;
          -  Child does not have other medical conditions that would preclude the child from&#xD;
             completing study assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The child does not meet the inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>33 Months</minimum_age>
    <maximum_age>39 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth McClure, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth McClure, PhD</last_name>
    <phone>919-316-3773</phone>
    <email>mcclure@rti.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Hoffman, MD</last_name>
    <phone>302-733-6510</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wally Carlo, MD</last_name>
      <email>wcarlo@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Wally Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia L. Hibberd, MD, PhD</last_name>
      <phone>617-636-2431</phone>
      <email>plh0@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia L. Hibberd, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Goldenberg, MD</last_name>
      <email>rlg88@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Goldenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinshasa School of Public Health</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>INCAP</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manolo Mazariegos, MD</last_name>
      <phone>011-502-849-8892</phone>
      <email>mmazarie@turbonett.com</email>
    </contact>
    <investigator>
      <last_name>Nancy Krebs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manolo Mazariegos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Medical College</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shivaprasad S Goudar, MD</last_name>
      <email>sgoudar@jnmc.edu</email>
    </contact>
    <investigator>
      <last_name>Shivaprasad Goudar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Derman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lata Medical Research Foundation</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Archana Patel, MD</last_name>
      <email>dr_apatel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Archana Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Hibberd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Saleem, M.D.</last_name>
      <email>sarah.saleem@aku.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Goldenberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Saleem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elwyn Chomba, MBChB</last_name>
      <email>echomba@zamnet.zm</email>
    </contact>
    <investigator>
      <last_name>Elwyn Chomba, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wally Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Pakistan</country>
    <country>United States</country>
    <country>Zambia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-eclampsia</keyword>
  <keyword>Low Dose Aspirin</keyword>
  <keyword>ASPIRIN Trail</keyword>
  <keyword>NICHD Global Network</keyword>
  <keyword>Global Network</keyword>
  <keyword>ASPRIN Follow Up</keyword>
  <keyword>BSID-III</keyword>
  <keyword>Family Resources and Context</keyword>
  <keyword>ASQ-36</keyword>
  <keyword>Neurodevelopmental delays</keyword>
  <keyword>hypertensive disorders of pregnancy (HDP)</keyword>
  <keyword>Pre-term birth</keyword>
  <keyword>LDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The plan is to release primary results from the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

